{"id":"NCT00805194","sponsor":"Boehringer Ingelheim","briefTitle":"LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer","officialTitle":"Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-03","primaryCompletion":"2010-11-02","completion":"2017-11-13","firstPosted":"2008-12-09","resultsPosted":"2014-12-01","lastUpdate":"2018-12-05"},"enrollment":1314,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"placebo plus docetaxel","otherNames":[]},{"type":"DRUG","name":"BIBF 1120 plus docetaxel","otherNames":[]}],"arms":[{"label":"BIBF 1120 plus docetaxel","type":"EXPERIMENTAL"},{"label":"Placebo plus docetaxel","type":"PLACEBO_COMPARATOR"}],"summary":"The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis.","primaryOutcome":{"measure":"Progression Free Survival (PFS) as Assessed by Central Independent Review","timeFrame":"From randomisation until cut-off date 2 November 2010 (when 713 PFS events were observed)","effectByArm":[{"arm":"Nintedanib Plus Docetaxel","deltaMin":3.4,"sd":null},{"arm":"Placebo Plus Docetaxel","deltaMin":2.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0019"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":34},"locations":{"siteCount":210,"countries":["Austria","Belarus","Belgium","Bulgaria","China","Croatia","Czechia","Denmark","France","Georgia","Germany","Greece","India","Israel","Italy","Lithuania","Poland","Portugal","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["28702806","24411639"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":224,"n":652},"commonTop":["Neutrophil count decreased","Diarrhoea","Fatigue","White blood cell count decreased","Nausea"]}}